Eisai Co (OTC:ESALF) Stock, Quote.Headers.trade-ideas

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Brain,Degenerative,Diseases,Parkinson,,Alzheimer,,Puzzle

Biotech

Large Cap

News

Health Care

General

BIIB

ESAIY

ESALF

The U.K.&#39;s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen&#39;s Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer&#39;s. Despite this, NICE stated the drug&#39;s benefits are too small to justify the cost for NHS use.

Biogen&#39;s Alzheimer&#39;s Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement

medical-bottles-syringe-seen-biogen-logo-displayed-440nw-13618678a

Movers

ESALY

The European Medicines Agency&#39;s CHMP has rejected the approval of Eisai and Biogen&#39;s Alzheimer&#39;s treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards making the treatment available in the EU, where Alzheimer&#39;s affects 6.9 million people.

Biogen/Eisai&#39;s Alzheimer&#39;s Drug Leqembi Gets &#39;No Go&#39; From European Drug Regulator&#39;s Advisory Panel, Cites Serious Side Events

Bernie Sanders

Politics

Bernie Sanders: &#39;Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings&#39;

Eisai Co Ltd

Biogen posts Q2 beat as sales from Alzheimer's drug pick up

Eisai Co Ltd (ESALF) Q1 2025 Earnings Call Transcript

Bristol Myers bid to expand label for liver cancer drug under FDA review

Miki Sogi, an analyst from Bernstein, maintained the Buy rating on Eisai Co (ESALF – Research Report). The associated price target is Yen9,600.00. ...

Eisai Co: A Strong Buy on Projected Margin Growth and Market Outperformance

Biogen/Eisai's Alzheimer's drug wins marketing authorization in Great Britain

Biogen, Eisai new Alzheimer's drug considered too costly in Britain

Eli Lilly Alzheimer's drug set to face same fate as Biogen's in U.K.: report

Healthcare company Eli Lilly's ($LLY) Alzheimer's drug, donanemab (marketed as Kisunla), could be rejected for use by the National Health Service (...

Eli Lilly's Alzheimer's Drug Could be Rejected by NHS

QIAGEN, Lilly to develop Alzheimer's risk detection test

Merck Keytruda with Eisai's Lenvima succeeds in late-stage trial for liver cancer

BAYRY

BAYZF

QGEN

SAGE

Lumbar Degenerative Disc Disease Market and Epidemiology 2032: Drugs, Clinical Trials, FDA Approval and Companies by DelveInsight | Spine BioPharma, MCRA, Synthes USA HQ, NuVasive, Globus Medical Inc, Spineology Inc, Ranier Technology Limited, DiscGenics, Invibio, Yuhan Corporation, Orthofix, Janssen Korea, Eisai, Angitia Biopharmaceuticals, Baxter Healthcare Corporation, Apatech, Zimmer Biomet

GMED

OFIX

Eisai Co

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Eisai Co

Eisai Co (ESALF) Forecast

Eisai Co (OTC:ESALF) Stock, Quote.Headers.trade-ideas